How much does Lijingqing (Ursodeoxycholic Acid Oral Suspension) Cost& price without insurance in China?
Lijingqing® is the domestic commercial brand name of Ursodeoxycholic Acid Oral Suspension, developed by CYNogen Bio. It is a hydrophilic natural bile acid preparation. It reduces the accumulation of toxic hydrophobic bile acids in hepatocytes, protects liver and bile duct cell membranes, promotes bile excretion, inhibits liver fibrosis progression, and relieves intrahepatic cholestatic liver injury.
Main Indications
Treatment of primary biliary cholangitis in adult patients without decompensated liver cirrhosis;
Treatment of liver disease associated with cystic fibrosis (CFALD) in pediatric and adult patients;
Treatment of radiolucent gallbladder cholesterol stones with normal gallbladder contractile function.
Clinical Research
A series of domestic multicenter Phase III clinical studies verified its efficacy and safety:
PBC pivotal trial: Long-term oral administration obviously improved liver biochemical indicators such as ALP, GGT and bilirubin, slowed liver fibrosis progression and lowered the risk of liver decompensation.
CFALD clinical trial: It is the only domestic oral suspension approved for cystic fibrosis-related liver disease, effectively alleviating intrahepatic cholestasis in children and adolescents with better compliance than solid formulations.
Formulation comparative study: The suspension shows faster absorption and higher bioavailability than tablets and capsules, suitable for children, the elderly and patients with swallowing disorders.
Long-term follow-up confirmed its controllable safety profile without severe irreversible hepatic adverse events.
Common Side Effects
Common mild adverse reactions: Loose stool, diarrhea, abdominal distension, nausea and mild skin pruritus;
Laboratory abnormalities: Transient mild elevation of liver enzymes (rare);
Severe but uncommon risks: Severe persistent diarrhea causing electrolyte imbalance, liver cirrhosis decompensation and allergic dermatitis.
Approval Status in China
Lijingqing® (Ursodeoxycholic Acid Oral Suspension, specification 250ml:12.5g) obtained marketing approval in China in April 2025. It is an oral prescription hepatobiliary drug for rare disease treatment.
Buy Lijingqing (Ursodeoxycholic Acid Oral Suspension) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
